Literature DB >> 28425825

Reviewing treatments and outcomes in the evolving landscape of ulcerative colitis.

Marla C Dubinsky1.   

Abstract

Ulcerative colitis (UC) is a chronic inflammatory disease extending proximally from the rectum to varying lengths of the colon that is characterized by alternating cycles of relapse and remission. Therapeutic goals for patients with active UC include induction and maintenance of remission and improvement in quality of life, as well as mucosal healing, a clinical outcome recently recognized in treatment guidance as being equally important. Mucosal healing is associated with favorable long-term patient outcomes related to remission, surgery, hospitalization, and quality of life. Given the increasing number of newer therapies available, it is important to properly position the use of each agent within the landscape of established UC therapies, evolving therapeutic goals, and established guidelines. Extent of disease is important to consider when selecting a treatment, as is an understanding of the short- and long-term outcomes (e.g. corticosteroid-free remission, mucosal healing) associated with each treatment. The purpose of this narrative review is to provide an overview of newer therapies for the treatment of UC and how they may best fit in the evolving landscape of UC.

Entities:  

Keywords:  Disease management; inflammatory bowel disease (IBD); mucosal healing; ulcerative colitis (UC); ulcerative colitis severity

Mesh:

Year:  2017        PMID: 28425825     DOI: 10.1080/00325481.2017.1319730

Source DB:  PubMed          Journal:  Postgrad Med        ISSN: 0032-5481            Impact factor:   3.840


  6 in total

1.  Natural dietary compound naringin prevents azoxymethane/dextran sodium sulfate-induced chronic colorectal inflammation and carcinogenesis in mice.

Authors:  Yu-Sheng Zhang; Feng Wang; Shu-Xiang Cui; Xian-Jun Qu
Journal:  Cancer Biol Ther       Date:  2018-04-25       Impact factor: 4.742

2.  Cost-Effectiveness Analysis of Vedolizumab Compared with Other Biologics in Anti-TNF-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan.

Authors:  Luis Hernandez; Hiroyo Kuwabara; Anshul Shah; Kaoru Yamabe; Heather Burnett; Kyle Fahrbach; Maria Koufopoulou; Ryuichi Iwakiri
Journal:  Pharmacoeconomics       Date:  2020-01       Impact factor: 4.981

3.  Retrospective Database Analysis: Dose Escalation and Adherence in Patients Initiating Biologics for Ulcerative Colitis.

Authors:  Millie D Long; Russell D Cohen; Timothy W Smith; Marco DiBonaventura; David Gruben; Danielle Bargo; Leonardo Salese; Daniel Quirk
Journal:  Dig Dis       Date:  2021-12-08       Impact factor: 3.421

4.  High Levels of Psychological Resilience Associated With Less Disease Activity, Better Quality of Life, and Fewer Surgeries in Inflammatory Bowel Disease.

Authors:  Priya Sehgal; Ryan C Ungaro; Carol Foltz; Brian Iacoviello; Marla C Dubinsky; Laurie Keefer
Journal:  Inflamm Bowel Dis       Date:  2021-05-17       Impact factor: 5.325

5.  Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT II.

Authors:  Walter Reinisch; William J Sandborn; Silvio Danese; Xavier Hébuterne; Maria Kłopocka; Dino Tarabar; Tomáš Vaňásek; Miloš Greguš; Paul A Hellstern; Joo Sung Kim; Miles P Sparrow; Kenneth J Gorelick; Michael Hoy; Martina Goetsch; Caleb Bliss; Charu Gupta; Fabio Cataldi; Séverine Vermeire
Journal:  J Crohns Colitis       Date:  2021-06-22       Impact factor: 9.071

6.  Biomarker dynamics during infliximab salvage for acute severe ulcerative colitis: C-reactive protein (CRP)-lymphocyte ratio and CRP-albumin ratio are useful in predicting colectomy.

Authors:  Danny Con; Bridgette Andrew; Steven Nicolaides; Daniel R van Langenberg; Abhinav Vasudevan
Journal:  Intest Res       Date:  2021-03-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.